title: Induction of micronuclei by 153Sm-EDTMP in peripheral blood lymphocytes of patients with bone metastases.
abstract: The purpose of this study was to evaluate the degree of cytological radiation damage to peripheral blood lymphocytes induced by 153Sm-EDTMP applied for palliation of metastatic bone pain. Blood samples from 16 patients (46-82 years old), 10 without previous radiotherapy and 6 with previous radiotherapy, were collected before and one hour after the administration of a mean activity of 41.7+/-5.8 MBq/kg of 153Sm-EDTMP. Then the lymphocytes were cultured for cytokinesis block micronucleus (MN) assay. The number of MNper binucleated cells (BC) in patients without previous radiotherapy before the treatment was of 0.030 (+/- 0.016) and after one hour 0.035 (+/- 0.013), although we could find inter individual differences. The basal MN/BC of the patients with no previous radiotherapy was similar to the controls. The increment in the percentage of BC with MN was similar in patients with and without previous radiotherapy. The observed mean of MN/BC is equivalent to a dose range of 0.05 to 0.10 Gy of 153Sm-EDTMP in vitro. The relatively low frequency of lymphocyte with micronuclei after the exposure to 153Sm-EDTMP supported the contention that radiation damage in lymphocytes of patients with painful bone metastases is minimal.
authors.affiliation: Department of Radiation Metrology, NM, CNEN, Instituto de Pesquisas Energéticas e Nucleares, Cidade Universitária, São Paulo, SP, Brazil. mfsuzuki@net.ipen.br
authors.forename: Miriam F
authors.initials: MF
authors.lastname: Suzuki
authors.forename: Márcia A
authors.initials: MA
authors.lastname: Silva
authors.forename: Daniella
authors.initials: D
authors.lastname: Murakami
authors.forename: Maria I C C
authors.initials: MI
authors.lastname: Guimaraes
authors.forename: Kayo
authors.initials: K
authors.lastname: Okazaki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001773:Blood Cells / Q000528:radiation effects; D001859:Bone Neoplasms / Q000097:blood / Q000532:radiotherapy* / Q000556:secondary; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D007963:Leukocytes, Mononuclear / Q000528:radiation effects; D008214:Lymphocytes / Q000528:radiation effects* / Q000648:ultrastructure; D008297:Male; D048629:Micronuclei, Chromosome-Defective / Q000528:radiation effects*; D008875:Middle Aged; D009942:Organometallic Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D010146:Pain / Q000209:etiology / Q000532:radiotherapy
chemical_list: D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; C061972:samarium Sm-153 lexidronam